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Abstract
The aim of this study was to screen for the presence of antimicrobial resistance genes within the saliva and faecal
microbiomes of healthy adult human volunteers from five European countries. Two non-culture based approaches were
employed to obviate potential bias associated with difficult to culture members of the microbiota. In a gene target-based
approach, a microarray was employed to screen for the presence of over 70 clinically important resistance genes in the
saliva and faecal microbiomes. A total of 14 different resistance genes were detected encoding resistances to six antibiotic
classes (aminoglycosides, b-lactams, macrolides, sulphonamides, tetracyclines and trimethoprim). The most commonly
detected genes were erm(B), blaTEM, and sul2. In a functional-based approach, DNA prepared from pooled saliva samples
was cloned into Escherichia coli and screened for expression of resistance to ampicillin or sulphonamide, two of the most
common resistances found by array. The functional ampicillin resistance screen recovered genes encoding components of a
predicted AcrRAB efflux pump. In the functional sulphonamide resistance screen, folP genes were recovered encoding
mutant dihydropteroate synthase, the target of sulphonamide action. The genes recovered from the functional screens
were from the chromosomes of commensal species that are opportunistically pathogenic and capable of exchanging DNA
with related pathogenic species. Genes identified by microarray were not recovered in the activity-based screen, indicating
that these two methods can be complementary in facilitating the identification of a range of resistance mechanisms present
within the human microbiome. It also provides further evidence of the diverse reservoir of resistance mechanisms present in
bacterial populations in the human gut and saliva. In future the methods described in this study can be used to monitor
changes in the resistome in response to antibiotic therapy.
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Introduction
The human body serves as a host for a diverse range of
commensal and symbiotic microorganisms, collectively termed the
microbiota. The microbiota is a natural component of the human
host that is acquired from birth onwards, and has important roles
in nutrition, development of the immune system, and protection
from colonisation by pathogens [1,2]. The microbiota can also
play a role in disease, as some members are opportunistic
pathogens that are capable of inducing disease following a
disturbance or disruption to their host (e.g. disease, wound or
medication) [3]. The microbiota contributes a small but significant
proportion to the host’s total mass and is estimated to contain ,10
fold more cells and ,100 fold more genes than the human host
[2]. The microbiome is the aggregate collection of genes within the
microbiota and the portion which encodes resistance to antibiotics
has been termed the resistome [4].
Although there is evidence that antimicrobial use in humans
and animals has had an impact upon the composition of the
microbiome [5], antimicrobial resistance (AMR) genes have been
detected in humans, animals, and in environments where there is
little or no evidence of antibiotic use by man [6–8]. However, it is
worth noting that in the latter study by Pallecchi et al [6–8] it was
concluded that the resistances seen in these remote communities
arose not due to an independent in situ selection but due to
dissemination of resistant bacteria and resistant genes from
antibiotic exposed settings, indicating the indirect effect of
antibiotic usage and exposure. The resistome is important in that
it acts as a reservoir of AMR genes that can reside in commensals
or opportunistic pathogens and can be acquired by pathogens via
horizontal gene transfer, and consequently has the potential to
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interfere with therapeutic options following infection. The
isolation of resistant bacteria by culture and subsequent elucida-
tion of resistance mechanisms has provided insight into the AMR
gene carriage of indicator organisms [8–11], however, as the
majority of the bacteria in the microbiota cannot be readily
cultivated, three approaches that do not rely on the culture of
isolates have been employed to study the resistome (reviewed in
[12,13]). PCR has been used to detect known AMR genes in the
resistome, in a target-based approach (reviewed in [12]). In a
sequenced-based approach, the microbiome is shotgun sequenced
and AMR genes identified by homology to known genes in
reference databases (reviewed in [13]). These two methods only
enable the detection of previously characterised genes and
therefore cannot fully explore the capacity of the resistome. In
functional-based screening, DNA prepared from the microbiota of
a particular ecological niche is ligated into a vector and
transformed into a heterologous host. The resultant clones are
screened for resistance to selected antibiotics. This approach
enables resistance genes to be identified without prior knowledge
of their sequence (reviewed in [14]) and has been used to recover
known and novel AMR genes from, for example, soil [15,16], an
activated sludge microbial community [17] and the human
microbiome [18,19].
The aim of this study was to screen the saliva and faecal
resistomes of healthy adult human volunteers for the presence of
AMR genes using target- and functional-based approaches. The
target-based approach employed a microarray capable of detect-
ing over 70 AMR genes in a single operation [20], to screen the
resistomes for a wide range of known, clinically important
resistance genes. This microarray has been used previously to
study bacterial isolates in epidemiological studies [21,22]. For the
functional-based approach, clones were screened for expressed
resistance to ampicillin and sulphonamide. In order to place
detected AMR genes within the context of the microbiota, the
microbial profiles of the samples studied were determined using
454 pyrosequencing of 16S rRNA gene amplicons.
Methods
Samples
The saliva and faecal samples employed in this study were
collected from five European countries (Finland, France, Italy,
Norway, and Scotland) as part of the EU FP6 Quality of Life
Management of Living resources QLK2-CT2002-00843 ‘‘Anti-
microbial resistance transfer from and between Gram-positive
bacteria of the digestive tract and consequences for virulence’’
project and have been described previously [23]. In brief, samples
of faeces and saliva were pooled from 20 healthy adult volunteers
in each country, who had not received antibiotic therapy in the
previous three months. DNA was prepared from the samples using
the Puregene DNA extraction kit (Gentra Systems supplied by
Flowgen, Nottingham, UK) as described previously [23]. Volun-
teers were given information on the study and all gave informed
consent [23], approval for the study in Scotland was provided by
the Grampian Research ethics committee (approval number
LREC NoL 003//060).
Microarray Procedure and Validation PCR
For each DNA preparation (see Table S1 for DNA concentra-
tions), 2.5 ml was amplified using the Illustra GenomiPhi HY DNA
Amplification Kit (GE Healthcare Life Sciences, Little Chalfont,
UK) according to the kit protocol. The amplified DNA (6.5 ml) was
then labelled in a linear multiplex reaction and added to the
microarrays for hybridisation, with signals from the hybridisation
duplex read on an ArrayMate (Alere Technologies, Jena,
Germany) using IconoClust software (Standard version; Alere
Technologies), as already described [20]. Mean signal intensities of
two replicate spots per probe were used for analysis. Intensities of
$0.2 were considered positive. The sensitivity of the amplification
and microarray method employed was estimated using a dilution
series of DNA extracts (25 ng to 0.025 ng) from two E. coli strains
of known AMR gene content (strains E111592 and 01-2571) in
500 ng calf thymus DNA (Sigma-Aldrich, Dorset, UK), and the
presence/absence of the expected genes at each dilution was
determined. PCR was performed on amplified DNA samples for
four genes using previously published primers to validate the array
approach: blaIMP, blaTEM, erm(B), and sul2 [20,22].
Library Construction and Functional-based Screening
A bacterial artificial chromosome (BAC) library was constructed
as described previously [24]. Briefly, the DNA prepared from
saliva samples from Finland, Italy, Norway, and Scotland was
pooled and partially digested with HindIII before ligation into
pCC1BAC using the CopyControl Ligation kit (Epicentre
Biotechnologies, Madison, WI, USA) according to the product
protocol. Ligations were transformed into electrocompetent E. coli
TransforMax EPI300-T1R cells (Epicentre Biotechnologies),
according to the product protocol and, following addition of
SOC medium, were allowed to recover for 1 hour at 37uC with
shaking horizontally at 225 rpm. Functional-based screening was
performed by plating the transformation reactions on Luria
Bertani (LB) agar with chloramphenicol (12.5 mg/ml) and either
ampicillin (25 mg/ml) or sulfamethoxazole (250 mg/ml) as appro-
priate and subsequent incubation at 37uC. Plates were checked at
24 and 48 hours after plating and resistant clones were recovered
and propagated at 37uC under the appropriate selection
(ampicillin at 25 mg/ml or sulfadiazine at 1024 mg/ml). The
transformation reaction was also plated on LB agar with
chloramphenicol (12.5 mg/ml), IPTG (0.1 M) and Xgal (40 mg/
ml) as controls. Based on these controls and the estimated average
insert size of 20 kb (unpublished data), the amount of DNA
surveyed in the ampicillin and sulphonamide functional-based
screens was estimated as 214 Mbp and 148 Mbp, respectively.
Susceptibility Testing of Recovered Clones
Recovered clones were tested for their susceptibility to a panel
of 12 antimicrobials (amikacin, amoxicillin/clavulanic acid,
ampicillin, cefotaxime, ceftazidime, chloramphenicol, ciprofloxa-
cin, gentamicin, nalidixic acid, streptomycin, trimethoprim/
sulphamethoxazole 1:19, and sulphonamide compounds) using
the British Society for Antimicrobial Chemotherapy (BSAC) disc
diffusion technique [25]. Susceptibility was defined using the
BSAC clinical breakpoints (the legacy breakpoint was used for
streptomycin), except with the sulphonamide compounds disc for
which the historical AHVLA veterinary breakpoint was used [26].
Antimicrobial susceptibilities of the reference strains E. coli EPI300
and E. coli EPI300 carrying an empty pCC1BAC vector were also
determined. E. coli EPI300 is inherently resistant to streptomycin
(conferred by a mutation in the rpsL gene) and trimethoprim
(engineered in as part of the trfA integration) (personal commu-
nication F. Hyde, Epicentre Biotechnologies). The pCC1BAC
vector has a chloramphenicol selectable marker.
BAC DNA Preparation, Sequencing and Analysis
Clones were cultured in LB medium supplemented with
chloramphenicol (12 mg/ml) and either ampicillin (25 mg/ml) or
sulfadiazine (1024 mg/ml) as appropriate. For BAC DNA prepa-
ration, 1 ml of an overnight culture was added to 9 ml LB medium
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with antibiotics and 10 ml copy control induction solution
(Epicentre Biotechnologies), then incubated at 37uC for 4 hours
according to the manufacturer’s protocol. BAC DNA was
recovered using the Qiaprep Spin Miniprep kit (Qiagen, Crawley,
UK) according to the kit protocol for low copy number plasmids.
The purified BAC DNA was fragmented by nebulization and
purified using Qiaquick purification columns (Qiagen, Crawley,
UK). Ends were repaired and 454-specific sequencing adapters
ligated using a Rapid Library Kit (Roche Diagnostics Ltd, Burgess
Hill, UK). The resultant library was sequenced on a Roche 454
GS FLX according to the manufacturer’s instructions (Roche
Diagnostics Ltd). The sequence reads were filtered for quality and
contigs generated using GSAssembler (v2.6, Roche Diagnostics
Ltd), using the manufacturer’s default settings. The cloned DNA
was trimmed of pCC1BAC host sequence. The RAST server [27]
was used to identify and annotate putative open reading frames
(ORFs) present in the insert DNA. The taxonomical classification
of each cloned DNA was determined by sequence homology and
ORF synteny using the RAST sequence-based comparison tools
[27]. The Basic Local Alignment Search Tool (BLAST) was
additionally used to annotate ORFs [28]. Predicted amino acid
sequences of ORFs were aligned using the ClustalV method of
MegAlign (Lasergene software, DNASTAR, Madison, WI, USA).
Determining the Composition of the Microbiotas
The taxonomic diversity present in the samples was assessed by
high-throughput sequencing of partial 16S rDNA gene amplicons
on a Roche 454 GS FLX platform. For this, the DNA extracted
from each sample was quantified and amplified with barcoded
universal primers for the V4 and V5 regions of the 16S rRNA
gene as described previously [29]. The Qiime pipeline version
1.5.0 [30] was used to process and analyse the 16S rRNA
sequence data. Sequences were binned by samples using the
sample-specific barcode sequences, trimmed of the barcode and
primer sequences, filtered (sequences required a length $300 bp,
no undetermined bases, and a perfect match to the barcode and
PCR primer), and denoised. Sequences were clustered into
operational taxanomic units (OTUs) using UCLUST [31] with a
97% sequence identity threshold. Chimeric sequences were
identified with ChimeraSlayer [32] and excluded from further
analysis. OTUs were assigned taxonomy using the Ribosomal
Database Project (RDP) classifier (minimum confidence of 80%)
[33] and the Greengenes database [34]. Based on the number of
sequences obtained per sample (see results), the relative OTU
abundance for each sample was determined at an even depth of
11070 sequences per sample (randomly picked without replace-
ment; OTUs observed less than five times were excluded from this
analysis).
Results
DNA-DNA Hybridisation-based Screen: Microarray of
Microbiomes
The sensitivity of the microarray method used was estimated
using spiked samples, and for two of the three replicates, the
majority ($70%) of the expected genes were detected when the
spike was present at 0.25 ng (Table S2). Although probes had
differing sensitivities, and some were positive only at higher
concentrations, no false positive results were obtained. This
indicates that, using this system, a bacterial AMR gene is
detectable if it comprises 0.05% of the total DNA in the test
sample. The saliva and faecal human DNA samples were tested
using this approach and AMR genes were detected in all samples
(Table 1; see Table S3 for all microarray results). Across all
samples, 14 different AMR genes were detected encoding
resistances to six antibiotic classes (aminoglycosides, b-lactams,
macrolides, sulphonamides, tetracyclines and trimethoprim;
Table 1). The average number of genes detected per sample was
four (range 1–8), encoding resistances to an average of three
antibiotic classes (range 1–6). The most commonly detected gene
was erm(B), encoding macrolide resistance, which was detected by
microarray in all ten samples and confirmed by PCR in eight
samples (two were not tested), as previously reported [23]. The
macrolide resistance genes, vatE and ereA, were each detected in a
single sample only. The sulphonamide resistance gene, sul2, was
the second most common gene and was detected in both the saliva
and faecal samples from France, Italy and Norway. PCR verified
the presence of sul2 in all these microarray positive samples and in
three microarray negative samples (Finland saliva, Finland faeces,
and Scotland faeces). The b-lactamase gene, blaTEM, was detected
by microarray in five samples. PCR verified the presence of blaTEM
in these samples and additionally detected blaTEM in four samples
(Scotland saliva, Italy faecal, Norway faecal, and Scotland faecal).
Sequence analysis of six of the blaTEM amplicons showed that they
were not Extended Spectrum b-lactamase variants (three not
sequenced; data not shown). The only other b-lactamase detected
was blaCMY/MOX in one sample. The b-lactamase blaIMP is
represented on the microarray by six probes and at least four are
required to be positive for the gene to be considered present. In
four samples, only one blaIMP probe had a signal .0.2 and
therefore this gene was recorded as absent (PCR verified that these
samples were negative for blaIMP). Tetracycline resistance genes
were detected in six of the ten samples tested, tet(B) was detected
only in saliva samples and tet(X) was detected mainly in faecal
samples. Five different aminoglycoside resistance genes were
detected: strA and strB in faecal samples; aadB, aac69-aph29, and
aac69-Ib in saliva samples. Additionally, one trimethoprim
resistance gene (dfrA14) was detected by microarray.
Functional-based Screen: Ampicillin
Five clones were recovered and propagated from the ampicillin
functional-based screening. The antimicrobial susceptibilities of
each clone were tested by disc diffusion, and three had
intermediate resistance to ampicillin (Table 2). The BACs from
these three clones were purified and sequenced. The size of the
inserts ranged from 9,476 bp to 16,716 bp and contained 7 to 13
predicted ORFs (Table 2). The cloned DNA in each BAC had
high homology (93–96% nucleotide sequence identity) and gene
synteny to the Haemophilus parainfluenzae genome. The clones
spanned, to differing extents, the same region of the H.
parainfluenzae genome. Six ORFs were shared by all three clones
and within this region, three ORFs with sequence homology to the
acrRAB operon were identified. The genes acrA and acrB encode
components of a multidrug efflux pump with a broad substrate
range, including ampicillin [35], and acrR encodes a transcrip-
tional repressor of the acrRAB operon [36,37]. The identity
between the predicted amino acid sequences of the cloned acrA
and acrB genes and that in H. parainfluenzae was $98.7% and
$98.4% respectively, while for acrR the identity was $88.5%, and
there were no mutations causing frame shifts or early translation
termination. The three remaining ORFs shared by the clones do
not have predicted functions related to ampicillin resistance and
putatively encode a primosomal protein N’ (PriA), a cell division
protein (FtsN), and a membrane-bound protease (HtpX). Conse-
quently, the acrRAB operon is predicted to confer the reduced
susceptibility to ampicillin observed in the three clones. Clone
AMP7 contained an IS5 element, which was not present in the
other two AMP clones and which was 100% identical in
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nucleotide sequence to IS5 elements from E. coli and is assumed to
have transposed into the insert from the genome of the E. coli host.
Functional-based Screen: Sulphonamide
From the sulphonamide functional-based screen a total of 23
resistant clones were recovered. The antimicrobial susceptibilities
of these clones were determined by disc diffusion. Seven clones
(SUL6, 8, 9, 10, 11, 15, and 20) were resistant to trimethoprim/
sulphonamide, and had reduced susceptibility (but not clinical
resistance) to sulphonamide compounds when compared to the E.
coli EPI300 wild-type. Two clones (SUL3 and 5) were resistant to
sulphonamide compounds and had reduced susceptibility (but not
clinical resistance) to trimethoprim/sulphonamide compared to
the EPI300 wild-type. The BACs from these nine clones were
sequenced.
The cloned DNA was taxonomically classified by sequence
homology and gene synteny: four clones were identified as
originating from Neisseria subflava (SUL6, SUL8, SUL9, and
SUL15), four clones from Veillonella parvula (SUL3, SUL5,
SUL10, and SUL20), and one clone from Streptococcus infantis
(SUL11). The size of the inserts ranged from 10,250 bp to
21,161 bp and contained 11 to 20 predicted ORFs, summarised in
Table 2.
All nine clones possessed the folP gene which encodes
dihydropteroate synthase (DHPS). DHPS catalyses an essential
step in the folic acid biosynthesis pathway and is the target of
sulphonamide action [38]. Certain mutant folP genes encode a
DHPS enzyme that has a lower affinity for sulphonamides, and
thus confer reduced susceptibility to this antibiotic. The predicted
DHPS amino acid sequences from the BACs were aligned with
DHPS sequences of representative folP genes (including sulphon-
amide susceptible and resistant variants) and analysed for the
presence of mutations that can confer reduced susceptibility to
sulphonamides (Figure 1).
The DHPS of the four N. subflava clones had 97.8 to 98.8%
amino acid identity to the DHPS encoded by a genome fragment
of N. subflava (strain NJ9703, accession number ACEO02000001).
Two amino acid substitutions were identified in the DHPS
sequences of the four clones: a phenylalanine to leucine
substitution at amino acid 31 and an arginine to serine substitution
at amino acid 228, Figure 1. These mutations have been described
previously in N. meningitidis and confer resistance to sulphonamides
[39]. Both mutations were also present in the N. subflava reference
DHPS sequence.
For the V. parvula clones, the DHPS had 94.4 to 95.6% amino
acid identity to the DHPS from the V. parvula type strain Pre´vot
Te3T (accession number CP001820). Two mutations with the
potential to confer resistance to sulphonamides were identified in
these DHPS sequences: insertion of phenylalanine after the glycine
at amino acid 189 and an arginine to glycine substitution at amino
acid 222. Neither mutation was present in the V. parvula type
strain. In V. parvula, amino acid 189 corresponds to amino acid 194
in N. meningitidis (Figure 1), and insertion of two amino acid
residues at this position confers resistance to sulphonamides in N.
meningitidis [39]. Amino acid 222 in the wild-type V. parvula DHPS
corresponds to amino acid 228 in N. meningitidis and mutations at
this residue can confer resistance to sulphonamides. Furthermore,
at the equivalent position in Streptococcus pyogenes, an arginine to
glycine substitution confers resistance to sulphonamides [40].
The predicted DHPS amino acid sequence of the single S.
infantis clone had 93.1% amino acid identity to the DHPS encoded
by a genome fragment from S. infantis (accession number
NZ_AEDY01000064). The DHPS from SUL11 did not possess
amino acid substitutions or insertions at the same positions where
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Figure 1. Alignment of the DHPS amino acid sequences from sulphonamide resistant BAC clones and representative DHPS
sequences. The numbering above the alignment is based on the DHPS sequence of the N. meningitidis strain BT054 and amino acids identical to this
sequence are indicated by a dot. Gaps are indicated by a hyphen. Amino acids discussed in the text are indicated by an asterisk above the
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mutants were identified in the N. subflava and V. parvula clones
(Figure 1). In the related species, Streptococcus pneumoniae, amino acid
duplications or insertions in the region spanning amino acids 58 to
67 confer resistance to sulphonamides [41], however no such
mutations were present in the SUL11 DHPS (Figure 1). Never-
theless a number of amino acid substitutions unique to the SUL11
DHPS were present which have not previously been ascribed to
sulphonamide resistant variants of streptococcal DHPS.
The folP gene present in each clone is therefore the likely
candidate to confer the observed reduced susceptibility or
resistance to sulphonamide. The reduced susceptibility or resis-
tance to trimethoprim/sulphonamide of the clones arises because
the E. coli EPI300 cells are inherently resistant to trimethoprim.
Composition of the Saliva and Faecal Microbiotas
The microbial profile of each sample was determined by
analysis of 16S rRNA gene sequences. From 11,076 to 84,755
sequences were obtained per sample (Table S3), following quality
control and removal of OTUs represented by less than five
sequences. For the saliva samples, the predominant taxa belonged
to Firmicutes (genus Streptococcus, Veillonella), Proteobacteria (genus
Neisseria, Haemophilus), Bacteroidetes (genus Prevotella, Porphyromonas),
and Fusobacteria (genus Fusobacterium) (Table S3 and Table S4).
In the faecal samples the predominant taxa belonged to
Bacteroidetes (genus Bacteroides, Prevotella) and Firmicutes (family
Lachnospiraceae, Ruminococcaceae, genus Faecalibacterium, Roseburia,
Lachnospira) (Table S4 and Table S5). The number of unclassified
sequences was small in the saliva samples (average 1.9%) but
comprised a significant proportion in the faecal samples (average
13.7%) (Table S3 and Table S4). In the saliva DNA used for
library construction, the average relative abundances for the
genera identified in the activity-based screens were: Haemophilus
spp. 7.3%, Neisseria spp. 9.0%, Veillonella spp. 10.8%, and
Streptococcus spp. 13.9%.
Discussion
A microarray was employed to rapidly screen the microbiome
of each sample for a panel of over 70 well characterised clinically
relevant AMR genes. Every sample was positive for one or more
AMR genes and in total genes encoding resistance to six antibiotic
classes was detected. Many of these genes have a global
distribution and have been reported in the human microbiota
previously, including aac69-lb, blaTEM, blaCMY/MOX, ereA, erm(B),
strA, strB, sul2, tet(B), and tet(X) [8–11,18,23,42–44]. These AMR
genes generally have broad host ranges and frequently reside on
mobile genetic elements such as plasmids and transposons [45].
These properties are likely to have contributed to their wide
prevalence and dissemination in human microbiomes. It is also
noteworthy that a large number of genes represented on the
microarray were not detected in these samples, including, for
example, those able to cover plasmid mediated resistance to
quinolones and carbapenems.
The microarray enabled a rapid screen for many AMR genes
but provided no direct information on their bacterial hosts, genetic
context, or whether they are inactivated by point mutations/
frameshifts. Additionally, sequenced-based methods such as
microarray (and PCR) only allow the detection of known genes.
Functional-based screens were therefore undertaken using antibi-
otics corresponding to those resistance genes identified by
microarray. However, in these screens the genes that had been
detected by microarray were not recovered. Instead the recovered
clones possessed chromosomally located genes, encoding efflux
pump proteins or a variant enzyme target of the antibiotic. For
clones expressing ampicillin resistance determinants, the H.
parainfluenzae acrRAB operon encoding a multi-drug efflux pump
was recovered. Genes encoding efflux pump proteins have been
recovered in other functional-based screens (reviewed in [14]). The
cloned predicted transcriptional repressor, AcrR, had ,90%
amino acid identity to the reference sequence, and may encode an
AcrR variant with impaired repressor activity, leading to increased
expression of the AcrAB pump. Increased activity of the AcrAB
multi-drug efflux pump contributes to the beta-lactamase-negative
ampicillin-resistant phenotype observed in some H. influenzae
clinical isolates [35]. The sulphonamide functional-based screen
returned clones from three species, each containing the chromo-
somally located folP gene encoding a mutant DHPS, the target of
sulphonamide action. Alterations in the target site of the antibiotic
that reduce its binding capacity are a general mechanism for
resistance, but, to our knowledge, have not been described
previously in clones recovered from functional screens [14].
All the resistance genes recovered by functional-based screening
were from commensal but opportunistically pathogenic species
from genera which were found by 16S rRNA gene 454
pyrosequencing to represent .7% of the microbiota in the
samples studied. Therefore bacteria from these species possess the
potential to compromise therapeutic options in the event of
disease. Furthermore the genes may be available for acquisition by
closely related bacteria, including pathogenic species, via natural
transformation, a mechanism of horizontal gene transfer. In
Haemophilus spp. and Neisseria spp., natural transformation is
mediated by distinct DNA uptake sequences [46,47], which were
present in multiple copies in each clone from these species.
Exchange of DNA between commensal streptococci and the major
human pathogen S. pneumoniae is also well documented [48] and
requires no specific uptake sequences. The folP from V. parvula
encoded a DHPS with novel mutations that gave resistance to
sulphonamides, which are not present in the wild-type strain
sequence. Resistance to sulphonamides in V. parvula has not been
extensively investigated [49], although Wu¨st and Wilkins [50]
reported an MIC for co-trimoxazole of four human isolates.
We hypothesise that the recovery of chromosomally located
genes in the functional screens reflects the abundance of the
sequences present within the microbiomes studied. Although genes
such as sul2 and blaTEM were sufficiently abundant to be detected
by microarray, they are expected to reside in a diverse set of hosts
and genetic environments. Consequently the abundance in any
given genetic environment for these genes is low and the use of
pooled DNA in the construction of the BAC library would have
further diluted this abundance. The microbial profiles obtained in
this study were in general agreement with those reported in other
studies of the healthy human saliva and faecal microbiomes
[42,51,52], and showed that the relative abundance of bacterial
genera is similar between the different samples so pooling was
numbering. SUL-R = sulphonamide resistant; SUL-S = sulphonamide susceptible; SUL-RS= reduced susceptibility to sulphonamide. The nucleotide
accession number and reference for the representative DHPS sequences used in the alignments are: N. meningitidis BT054 (X68067; [54]), N.
meningitidis MO035 (X68062; [54]), N. meningitidis NM419 (AY722006; [39]), N. subflava NJ9703 (ACEO02000001; direct submission), V. parvula Te3T
(CP001820; [49]), S. pneumoniae 708 (U16156; [55]), S. pneumoniae WA-152 (AJ311336; [41]), S. pyogenes G1 (AJ000686; [40]), S. pyogenes G56
(AJ000685; [40]), and S. infantis SK1302 (NZ_AEDY01000064; direct submission).
doi:10.1371/journal.pone.0086428.g001
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expected to have had a minimal effect on the relative abundance
of chromosomal genes. The use of pooled samples will have also
reduced the sensitivity of the microarray assay, allowing the
detection of only the most prevalent genes. PCR validated the
microarray positive results for four genes; however, some
microarray negative samples were PCR positive. This is likely to
be a consequence of the greater sensitivity of the PCR method
(PCR product accumulation is geometric/exponential, while for
microarray labelling product accumulation is arithmetic). In future
we would propose using the microarray with DNA preparations
from a single subject only.
A powerful advantage of function-based screening is that genes
can be recovered without prior knowledge of their sequence.
However, a drawback to this approach is that it requires the
cloned genes to be expressed and the gene products to be active in
the heterologous host, and considerations such as codon usage,
promoter sequences and interactions with other proteins can all
influence the recovery of clones. For example, the H. influenzae
AcrAB can confer resistance to several antimicrobials when
expressed in E. coli, but requires the host encoded TolC protein
for this activity [53]. In this study we cloned large fragments of
DNA, as this would place any resistance gene identified in context
and facilitate identification of the host bacterium. The expression
of these cloned genes is therefore likely to be directed by their
natural promoters, which must be functional in the E. coli host. An
alternative strategy is to clone smaller inserts into expression
vectors and this can increase clone recovery but provides less
information on the origin of the clone.
In this study we have employed two methods to screen for AMR
genes in the resistome of healthy humans. The microarray was
used as a target-based strategy, to enable a rapid and broad survey
of AMR gene content, and provided insight into the diversity of
resistances present. However, this approach did not inform on the
bacterial hosts possessing these genes, nor on whether the genes
detected were intact and expressed in their host. In the functional-
based screens intact genes that expressed resistance (or reduced
susceptibility) were recovered and the bacterial hosts identified,
although this approach has its own limitations (as discussed above).
The target- and functional-based approaches we employed have
differing shortcomings and advantages; however they can com-
plement each other and together allowed a broad range of
resistance genes and mechanisms to be identified. This study
provides further evidence that the microbiome of healthy humans
harbours a diverse reservoir of resistance mechanisms, some of
which are present in populations from several different countries.
The techniques described in this study could be employed, in
future, to monitor the changes in the resistome in response to
antibiotic therapy, and can be employed alongside other methods
investigating the microbiota and microbiome.
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sequencing and the relative abundance of sequences
taxonomically classified to phyla at an even depth of
11070 sequences per sample.
(XLSX)
Table S5 Table of the relative abundance of sequences
taxonomically classified to genus or next highest
possible resolution level (family, order, or class).
(XLSX)
Acknowledgments
The authors wish to thank Drs. Adam P. Roberts and Lena Ciric
(Department of Microbial Diseases, University College London) for
providing the DNA extracts; Mrs. Muriel Mafura (Department of
Bacteriology, AHVLA) for performing the susceptibility testing; and Dr.
Richard J. Ellis (Central Sequencing Unit, AHVLA) for providing the
sequencing services at AHVLA Weybridge laboratory.
Author Contributions
Conceived and designed the experiments: MA EA PM. Performed the
experiments: RC PW NM. Analyzed the data: RC PW MA. Contributed
reagents/materials/analysis tools: RC NK PW. Wrote the paper: RC PW
EA PM MA.
References
1. Cho I, Blaser MJ (2012) The human microbiome: at the interface of health and
disease. Nat Rev Genet 13: 260–270.
2. Xu J, Gordon JI (2003) Honor thy symbionts. Proc Natl Acad Sci U S A 100:
10452–10459.
3. Brown SP, Cornforth DM, Mideo N (2012) Evolution of virulence in
opportunistic pathogens: generalism, plasticity, and control. Trends Microbiol
20: 336–342.
4. Wright GD (2010) The antibiotic resistome. Expert Opin Drug Discov 5: 779–
788.
5. Forslund K, Sunagawa S, Kultima JR, Mende DR, Arumugam M, et al. (2013)
Country-specific antibiotic use practices impact the human gut resistome.
Genome Res 23: 1163–1169.
6. Glad T, Bernhardsen P, Nielsen KM, Brusetti L, Andersen M, et al. (2010)
Bacterial diversity in faeces from polar bear (Ursus maritimus) in Arctic
Svalbard. BMC Microbiol 10: 10.
7. Bhullar K, Waglechner N, Pawlowski A, Koteva K, Banks ED, et al. (2012)
Antibiotic resistance is prevalent in an isolated cave microbiome. PLoS One 7:
e34953.
8. Pallecchi L, Lucchetti C, Bartoloni A, Bartalesi F, Mantella A, et al. (2007)
Population structure and resistance genes in antibiotic-resistant bacteria from a
remote community with minimal antibiotic exposure. Antimicrob Agents
Chemother 51: 1179–1184.
9. Bailey JK, Pinyon JL, Anantham S, Hall RM (2010) Commensal Escherichia
coli of healthy humans: a reservoir for antibiotic-resistance determinants. J Med
Microbiol 59: 1331–1339.
10. Kirchner M, Mafura M, Hunt T, Card R, Anjum MF (2013) Antibiotic
resistance gene profiling of faecal and oral anaerobes collected during an
antibiotic challenge trial. Anaerobe 23: 20–22.
11. Zhang L, Kinkelaar D, Huang Y, Li Y, Li X, et al. (2011) Acquired antibiotic
resistance: are we born with it? Appl Environ Microbiol 77: 7134–7141.
12. Penders J, Stobberingh EE, Savelkoul PH, Wolffs PF (2013) The human
microbiome as a reservoir of antimicrobial resistance. Front Microbiol 4: 87.
13. Schmieder R, Edwards R (2012) Insights into antibiotic resistance through
metagenomic approaches. Future Microbiol 7: 73–89.
14. Pehrsson EC, Forsberg KJ, Gibson MK, Ahmadi S, Dantas G (2013) Novel
resistance functions uncovered using functional metagenomic investigations of
resistance reservoirs. Front Microbiol 4: 145.
15. Allen HK, Moe LA, Rodbumrer J, Gaarder A, Handelsman J (2009) Functional
metagenomics reveals diverse beta-lactamases in a remote Alaskan soil. ISME J
3: 243–251.
16. Donato JJ, Moe LA, Converse BJ, Smart KD, Berklein FC, et al. (2010)
Metagenomic analysis of apple orchard soil reveals antibiotic resistance genes
encoding predicted bifunctional proteins. Appl Environ Microbiol 76: 4396–
4401.
Sampling the Resistome
PLOS ONE | www.plosone.org 8 January 2014 | Volume 9 | Issue 1 | e86428
17. Parsley LC, Consuegra EJ, Kakirde KS, Land AM, Harper WF, Jr., et al. (2010)
Identification of diverse antimicrobial resistance determinants carried on
bacterial, plasmid, or viral metagenomes from an activated sludge microbial
assemblage. Appl Environ Microbiol 76: 3753–3757.
18. Sommer MO, Dantas G, Church GM (2009) Functional characterization of the
antibiotic resistance reservoir in the human microflora. Science 325: 1128–1131.
19. Diaz-Torres ML, McNab R, Spratt DA, Villedieu A, Hunt N, et al. (2003) Novel
tetracycline resistance determinant from the oral metagenome. Antimicrob
Agents Chemother 47: 1430–1432.
20. Card R, Zhang J, Das P, Cook C, Woodford N, et al. (2013) Evaluation of an
expanded microarray for detecting antibiotic resistance genes in a broad range
of gram-negative bacterial pathogens. Antimicrob Agents Chemother 57: 458–
465.
21. Anjum MF, Choudhary S, Morrison V, Snow LC, Mafura M, et al. (2011)
Identifying antimicrobial resistance genes of human clinical relevance within
Salmonella isolated from food animals in Great Britain. J Antimicrob Che-
mother 66: 550–559.
22. Batchelor M, Hopkins KL, Liebana E, Slickers P, Ehricht R, et al. (2008)
Development of a miniaturised microarray-based assay for the rapid
identification of antimicrobial resistance genes in Gram-negative bacteria.
Int J Antimicrob Agents 31: 440–451.
23. Seville LA, Patterson AJ, Scott KP, Mullany P, Quail MA, et al. (2009)
Distribution of tetracycline and erythromycin resistance genes among human
oral and fecal metagenomic DNA. Microb Drug Resist 15: 159–166.
24. Warburton P, Roberts AP, Allan E, Seville L, Lancaster H, et al. (2009)
Characterization of tet(32) genes from the oral metagenome. Antimicrob Agents
Chemother 53: 273–276.
25. Anonymous (2012) BSAC methods for antimicrobial susceptibility testing,
version 11.1, May 2012. Birmingham, United Kingdom.: British Society for
Antimicrobial Chemotherapy.
26. Jones YE, Chappell S, McLaren IM, Davies RH, Wray C (2002) Antimicrobial
resistance in Salmonella isolated from animals and their environment in England
and Wales from 1988 to 1999. Vet Rec 150: 649–654.
27. Aziz RK, Bartels D, Best AA, DeJongh M, Disz T, et al. (2008) The RAST
Server: rapid annotations using subsystems technology. BMC Genomics 9: 75.
28. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ (1990) Basic local
alignment search tool. J Mol Biol 215: 403–410.
29. Ellis RJ, Bruce KD, Jenkins C, Stothard JR, Ajarova L, et al. (2013) Comparison
of the distal gut microbiota from people and animals in Africa. PLoS One 8:
e54783.
30. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, et al. (2010)
QIIME allows analysis of high-throughput community sequencing data. Nat
Methods 7: 335–336.
31. Edgar RC (2010) Search and clustering orders of magnitude faster than BLAST.
Bioinformatics 26: 2460–2461.
32. Haas BJ, Gevers D, Earl AM, Feldgarden M, Ward DV, et al. (2011) Chimeric
16S rRNA sequence formation and detection in Sanger and 454-pyrosequenced
PCR amplicons. Genome Res 21: 494–504.
33. Wang Q, Garrity GM, Tiedje JM, Cole JR (2007) Naive Bayesian classifier for
rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl
Environ Microbiol 73: 5261–5267.
34. DeSantis TZ, Hugenholtz P, Larsen N, Rojas M, Brodie EL, et al. (2006)
Greengenes, a chimera-checked 16S rRNA gene database and workbench
compatible with ARB. Appl Environ Microbiol 72: 5069–5072.
35. Kaczmarek FS, Gootz TD, Dib-Hajj F, Shang W, Hallowell S, et al. (2004)
Genetic and molecular characterization of beta-lactamase-negative ampicillin-
resistant Haemophilus influenzae with unusually high resistance to ampicillin.
Antimicrob Agents Chemother 48: 1630–1639.
36. Ramos JL, Martinez-Bueno M, Molina-Henares AJ, Teran W, Watanabe K, et
al. (2005) The TetR family of transcriptional repressors. Microbiol Mol Biol Rev
69: 326–356.
37. Dean CR, Narayan S, Daigle DM, Dzink-Fox JL, Puyang X, et al. (2005) Role
of the AcrAB-TolC efflux pump in determining susceptibility of Haemophilus
influenzae to the novel peptide deformylase inhibitor LBM415. Antimicrob
Agents Chemother 49: 3129–3135.
38. Skold O (2001) Resistance to trimethoprim and sulfonamides. Vet Res 32: 261–
273.
39. Fiebelkorn KR, Crawford SA, Jorgensen JH (2005) Mutations in folP associated
with elevated sulfonamide MICs for Neisseria meningitidis clinical isolates from
five continents. Antimicrob Agents Chemother 49: 536–540.
40. Swedberg G, Ringertz S, Skold O (1998) Sulfonamide resistance in
Streptococcus pyogenes is associated with differences in the amino acid
sequence of its chromosomal dihydropteroate synthase. Antimicrob Agents
Chemother 42: 1062–1067.
41. Haasum Y, Strom K, Wehelie R, Luna V, Roberts MC, et al. (2001) Amino acid
repetitions in the dihydropteroate synthase of Streptococcus pneumoniae lead to
sulfonamide resistance with limited effects on substrate K(m). Antimicrob Agents
Chemother 45: 805–809.
42. Jakobsson HE, Jernberg C, Andersson AF, Sjolund-Karlsson M, Jansson JK, et
al. (2010) Short-term antibiotic treatment has differing long-term impacts on the
human throat and gut microbiome. PLoS One 5: e9836.
43. Arthur M, Andremont A, Courvalin P (1987) Distribution of erythromycin
esterase and rRNA methylase genes in members of the family Enterobacteri-
aceae highly resistant to erythromycin. Antimicrob Agents Chemother 31: 404–
409.
44. Aminov RI (2009) The role of antibiotics and antibiotic resistance in nature.
Environ Microbiol 11: 2970–2988.
45. van Hoek AH, Mevius D, Guerra B, Mullany P, Roberts AP, et al. (2011)
Acquired antibiotic resistance genes: an overview. Front Microbiol 2: 203.
46. Danner DB, Smith HO, Narang SA (1982) Construction of DNA recognition
sites active in Haemophilus transformation. Proc Natl Acad Sci U S A 79: 2393–
2397.
47. Duffin PM, Seifert HS (2010) DNA uptake sequence-mediated enhancement of
transformation in Neisseria gonorrhoeae is strain dependent. J Bacteriol 192:
4436–4444.
48. Donati C, Hiller NL, Tettelin H, Muzzi A, Croucher NJ, et al. (2010) Structure
and dynamics of the pan-genome of Streptococcus pneumoniae and closely
related species. Genome Biol 11: R107.
49. Gronow S, Welnitz S, Lapidus A, Nolan M, Ivanova N, et al. (2010) Complete
genome sequence of Veillonella parvula type strain (Te3). Stand Genomic Sci 2:
57–65.
50. Wust J, Wilkins TD (1978) Susceptibility of anaerobic bacteria to sulfameth-
oxazole/trimethoprim and routine susceptibility testing. Antimicrob Agents
Chemother 14: 384–390.
51. Keijser BJ, Zaura E, Huse SM, van der Vossen JM, Schuren FH, et al. (2008)
Pyrosequencing analysis of the oral microflora of healthy adults. J Dent Res 87:
1016–1020.
52. Tap J, Mondot S, Levenez F, Pelletier E, Caron C, et al. (2009) Towards the
human intestinal microbiota phylogenetic core. Environ Microbiol 11: 2574–
2584.
53. Dastidar V, Mao W, Lomovskaya O, Zgurskaya HI (2007) Drug-induced
conformational changes in multidrug efflux transporter AcrB from Haemophilus
influenzae. J Bacteriol 189: 5550–5558.
54. Radstrom P, Fermer C, Kristiansen BE, Jenkins A, Skold O, et al. (1992)
Transformational exchanges in the dihydropteroate synthase gene of Neisseria
meningitidis: a novel mechanism for acquisition of sulfonamide resistance.
J Bacteriol 174: 6386–6393.
55. Lopez P, Espinosa M, Greenberg B, Lacks SA (1987) Sulfonamide resistance in
Streptococcus pneumoniae: DNA sequence of the gene encoding dihydroptero-
ate synthase and characterization of the enzyme. J Bacteriol 169: 4320–4326.
Sampling the Resistome
PLOS ONE | www.plosone.org 9 January 2014 | Volume 9 | Issue 1 | e86428
